"As state legislative
sessions in 2020 largely focused on [COVID-19], we saw limited action on drug
pricing overall. Looking to 2021, states are likely to refocus on some of these
drug pricing and affordability board measures, particularly as states continue
to seek opportunities to control costs."
— Megan Olsen, an associate principal in Avalere Health's policy
practice, spoke with AIS's RADAR
on Drug Benefits about actions states may take to control drug
spending in 2021.
Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment